Skip to main content
. 2016 Mar 8;7(15):20561–20573. doi: 10.18632/oncotarget.7987

Figure 4. Targeted inhibition of RalA attenuates CML malignant progression and sensitizes K562 cells to imatinib treatment.

Figure 4

(A) Inhibition of RalA sensitizes K562 cells to imatinib. K562 cells transfected with control, RalA siRNA or miR-181a were treated with different concentrations of imatinib (0–0.25 μM) for 24 h and the viability of cells was determined by MTT assay. (B) Inhibition of RalA reduces CML cell migration. A total of 6 × 105 K562 cells transfected with control, RalA siRNA or miR-181a were seeded into the upper chambers, counted after 24 h, followed by counting of cell numbers in the lower chambers. (C) Inhibition of RalA reduces CML cell invasion. A total of 3 × 105 cells transfected with control, RalA siRNA, or miR-181a were seeded into the upper chambers coated with Matrigel, stained with hematoxylin and counted after 8 h. (D) Inhibition of RalA reduces K562 cell colony formation. A total of 1000 K562 cells transfected with control, RalA siRNA, or miR-181a were mixed with RPMI-1640 medium containing 0.9% methylcellulose solution and 20% FBS, and seeded onto 24-well plates. Colony numbers were counted after 1 week. Histogram and statistics indicating the relative number of colonies per 1000 plated cells are shown in the lower panel. Statistical significance was assessed by one-way ANOVA (*p < 0.05).